Closed · RFA-FD-17-006 · CFDA 93.103 · Discretionary
Developing Biomarkers for Trastuzumab-induced Cardiotoxicity
Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.
- $140K-$140K
- Award range
- Closed
- Status
- July 24, 2017
- Close date
- 1
- Expected awards
The verdict
Developing Biomarkers for Trastuzumab-induced Cardiotoxicity is a closed discretionary listing from Food and Drug Administration that offered $140,000 -- $140,000 across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.
- $140K-$140K
- award range
- Closed
- application status
- 1
- expected award
- 93.103
- CFDA program
Archived opportunity record
Developing Biomarkers for Trastuzumab-induced… is closed (last close July 24, 2017). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed July 24, 2017
Est. Total Funding
$140,000
Expected Awards
1
Instrument
Grant
Description
This award is intended to provide support to conduct clinical studies at a clinical site with capability and patients samples to investigate potential biomarker (cMLC1) for trastuzumab-induced cardiotoxicity. 1) There will be an establishment of the assay to quantitatively measure cMLC-1 in humans. 2) Investigations will be conducted to determine the value of cMLC-1 in humans as an early predictor of cardiotoxicity in a pilot study. A comparison will be done of the level of cMLC-1 in 5 patients who subsequently developed cardiotoxicity and 5 patients who did not. Patients will be matched for age. Cardiotoxicity was defined using the Cardiac Review and Evaluation Committee for Trastuzumab (CREC) criteria as a decrease of more than 10% in the echocardiographic left ventricular ejection fraction to a value of less than 55%. 3) Women were monitored every 3 months for 15 months. 4) The archived plasma samples collected at multiple time points indicated below schematically will be tested for the biomarker cMLC-1 and for troponin I, an established marker for heart muscle damage as a control.
Catch-all / unrestricted eligibility mark · RFA-FD-17-006
Grants.gov marks Developing Biomarkers for Trastuzumab-induced… with a catch-all / unrestricted eligibility code (Others (see official listing text)). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Agriculture · Consumer Protection · Food and Nutrition (AG;CP;FN). 119 other Food and Drug Administration listings share this eligibility-code string (25% of 482).
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Food and Drug Administration Research
U.S. Department of Health and Human Services
Agency Contact
Shashi Malhotra Grants Management Specialist Phone( 240)402-7592
More from Food and Drug Administration
Federal and University Partnership to Improve the Safety of Seafood from the Gulf of America
Research, Education, and Outreach on Botanical Natural Products
Cooperative Agreement to Support Shellfish Safety Assistance Project
Education and Outreach to Tribal Producers through the Tribal Food Safety Alliance
Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional
What to do next
Developing Biomarkers for Trastuzumab-induced… is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
- Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
- Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |